Grantham, Mayo, Van Otterloo & Co (GMO)
GSK icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s GSK GSK Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$194M Buy
3,522,566
+33,192
+1% +$1.8M 0.5% 34
2025
Q4 		$171M Buy
3,489,374
+917,248
+36% +$42.8M 0.44% 33
2025
Q3 		$111M Sell
2,572,126
-29,449
-1% -$1.15M 0.31% 37
2025
Q2 		$99.9M Buy
2,601,575
+460,904
+22% +$17.6M 0.3% 39
2025
Q1 		$82.9M Sell
2,140,671
-2,012,945
-48% -$73.7M 0.26% 41
2024
Q4 		$140M Buy
4,153,616
+446,568
+12% +$16.1M 0.46% 32
2024
Q3 		$152M Buy
3,707,048
+561,718
+18% +$23M 0.48% 33
2024
Q2 		$121M Buy
3,145,330
+1,636,365
+108% +$68.8M 0.41% 39
2024
Q1 		$64.7M Sell
1,508,965
-169,984
-10% -$7.01M 0.24% 60
2023
Q4 		$62.2M Buy
1,678,949
+412,505
+33% +$14.8M 0.27% 60
2023
Q3 		$45.9M Buy
1,266,444
+634,070
+100% +$22.5M 0.22% 83
2023
Q2 		$22.5M Buy
632,374
+473,664
+298% +$17M 0.1% 171
2023
Q1 		$5.65M Sell
158,710
-144,700
-48% -$5.06M 0.03% 306
2022
Q4 		$10.7M Sell
303,410
-1,837,510
-86% -$61.2M 0.06% 226
2022
Q3 		$63M Buy
2,140,920
+582,520
+37% +$22.1M 0.36% 54
2022
Q2 		$84.8M Buy
1,558,400
+1,132,240
+266% +$62.5M 0.46% 45
2022
Q1 		$23.2M Buy
426,160
+238,880
+128% +$13M 0.11% 171
2021
Q4 		$10.3M Sell
187,280
-43,840
-19% -$2.28M 0.05% 252
2021
Q3 		$11M Sell
231,120
-243,920
-51% -$12.3M 0.05% 237
2021
Q2 		$23.6M Buy
475,040
+281,760
+146% +$13.5M 0.12% 146
2021
Q1 		$8.62M Buy
193,280
+162,000
+518% +$7.35M 0.05% 249
2020
Q4 		$1.44M Buy
31,280
+1,120
+4% +$51.4K 0.01% 504
2020
Q3 		$1.42M Sell
30,160
-68,880
-70% -$3.45M 0.01% 463
2020
Q2 		$5.05M Sell
99,040
-269,280
-73% -$13.8M 0.04% 242
2020
Q1 		$17.4M Buy
368,320
+211,120
+134% +$11.3M 0.15% 96
2019
Q4 		$9.23M Sell
157,200
-461,226
-75% -$25.7M 0.06% 201
2019
Q3 		$33M Sell
618,426
-1,064,320
-63% -$54.8M 0.23% 69
2019
Q2 		$84.2M Sell
1,682,746
-282,960
-14% -$14.2M 0.59% 42
2019
Q1 		$103M Sell
1,965,706
-36,960
-2% -$1.85M 0.74% 34
2018
Q4 		$95.7M Buy
2,002,666
+56,560
+3% +$2.79M 0.76% 36
2018
Q3 		$97.7M Buy
1,946,106
+580,506
+43% +$29.5M 0.66% 43
2018
Q2 		$68.8M Buy
1,365,600
+157,040
+13% +$7.91M 0.49% 49
2018
Q1 		$59M Buy
1,208,560
+356,800
+42% +$16.6M 0.36% 58
2017
Q4 		$37.8M Buy
851,760
+189,440
+29% +$8.75M 0.22% 78
2017
Q3 		$33.6M Buy
662,320
+418,480
+172% +$21.2M 0.2% 89
2017
Q2 		$13.1M Sell
243,840
-244,480
-50% -$13M 0.07% 157
2017
Q1 		$25.7M Sell
488,320
-967,819
-66% -$49.1M 0.15% 119
2016
Q4 		$70.1M Buy
1,456,139
+205,470
+16% +$10.1M 0.38% 70
2016
Q3 		$67.4M Buy
1,250,669
+1,126,765
+909% +$61.8M 0.32% 79
2016
Q2 		$6.71M Buy
123,904
+59,984
+94% +$3.16M 0.03% 270
2016
Q1 		$3.24M Buy
+63,920
New +$3.18M 0.01% 335

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s GSK Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its GSK (GSK) stake by 0.95% in Q1 2026, buying an estimated $1.8M and bringing the position to 3,522,566 shares worth $194M. The position accounts for 0.5% of the portfolio, ranked #34.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in GSK in Q1 2016 and has held it in 41 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 3,522,566 shares of GSK worth $194M as of Q1 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) bought 33,192 GSK shares in Q1 2026, an estimated $1.8M.
  • GSK made up 0.5% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #34 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in GSK in Q1 2016 and has held it in 41 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.